NanoVibronix announced that its application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved. The company also confirmed that the contract with NHS Supply Chain for the supply of UroShield through the company’s U.K. distribution partner, Peak Medical Limited, has been extended for up to four years. Drug Tariff provides for full reimbursement of UroShield actuators by the NHS. Clinicians in the U.K. will be able to prescribe the products, which are used in conjunction with the UroShield device, beginning November 1, 2023. Both hospital and community clinicians will have the option of prescribing UroShield either through the prescription process or through the NHS contract. Importantly, wherever a patient is treated, they can now receive the full UroShield system with the NHS paying the cost and not the patient. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, ”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NAOV:
- NanoVibronix files to sell 8.96M shares of common stock for holders
- NanoVibronix announces presentation of UroShield testing results at ICS
- NanoVibronix to sell 2.91M shares and warrants at $1.72 per share
- NanoVibronix says PainShield not reimbursable under Medicare, Medicaid
- NanoVibronix extends distribution agreement with Ultra Pain Products